PRECISESADS’ consortium represents a range of partner organisations of high scientific reputation in the field, and with experience in undertaking large human cohort studies, 2 SMEs, and 5 major pharmaceutical companies. The coordinator of the consortium is Dr. Chris Chamberlain, VP Head of Experimental Medicine and Diagnostics at UCB. The managing entity is led by Dr. Marta E. Alarcón-Riquelme, Head of the Department of Medical Genomics at GENYO (Genomic and Oncological Research centre), administered by the FPS.
The PRECISESADS governance structure has been designed to effectively integrate the Public consortium, EFPIA and academic/SME members. To facilitate inclusiveness of membership in the Consortium, PRECISESADS will be managed on a tiered structure, comprising a Steering Committee (SC) a General Assembly (GA) and a Project Office (PO). The Project Office (PO) will be the central contact point for administrative, financial, scientific, and contractual concerns of the consortium members and Committees. Closer to the actual activities will be the Working groups.